Trial Profile
Effect of Alirocumab on Reverse Cholesterol Transport in Humans
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2018
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Atherosclerosis; Coronary artery disease
- Focus Therapeutic Use
- 05 Nov 2018 Status changed from active, no longer recruiting to completed.
- 07 May 2018 Planned End Date changed from 1 Dec 2017 to 13 Aug 2018.
- 07 May 2018 Planned primary completion date changed from 1 Nov 2017 to 4 Jun 2018.